[HTML][HTML] Improving outcomes of tyrosine kinase inhibitors in hepatocellular carcinoma: new data and ongoing trials

L Mou, X Tian, B Zhou, Y Zhan, J Chen, Y Lu… - Frontiers in …, 2021 - frontiersin.org
Targeted therapies such as oral tyrosine kinase inhibitors (TKIs) are the main therapeutic
strategy effective for advanced hepatocellular carcinoma (HCC). Currently six tyrosine …

[HTML][HTML] Nanotechnology in tumor biomarker detection: The potential of liganded nanoclusters as nonlinear optical contrast agents for molecular diagnostics of cancer

GF Combes, AM Vučković, M Perić Bakulić, R Antoine… - Cancers, 2021 - mdpi.com
Simple Summary The key factor in preventing premature death from cancer is an early and
accurate diagnosis. While common diagnostic procedures are successful in the detection …

Activation/inactivation of anticancer drugs by CYP3A4: influencing factors for personalized cancer therapy

F Wang, X Zhang, Y Wang, Y Chen, H Lu… - Drug Metabolism and …, 2023 - ASPET
Cytochrome P450 3A4 (CYP3A4), one of the most important members of the cytochrome
P450 subfamily, is a crucial catalyst in the metabolism of numerous drugs. As it catalyzes …

[HTML][HTML] Comparative safety of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis

K Krawczyk, K Śladowska, P Holko… - Frontiers in …, 2023 - frontiersin.org
Objective: This study aimed to compare the safety profile of tyrosine kinase inhibitors (TKIs)
approved for use as monotherapy or combination therapy for the first-line treatment of adult …

Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma

ZB Zengin, A Chehrazi-Raffle, NJ Salgia… - … Oncology: Seminars and …, 2022 - Elsevier
The management of urothelial carcinoma (UC) has rapidly advanced in recent years with
new approvals for immune checkpoint inhibitors and antibody-drug conjugates. However …

[HTML][HTML] Overview of drug-drug interactions between ritonavir-boosted Nirmatrelvir (Paxlovid) and targeted therapy and supportive care for lung cancer

K Anwar, L Nguyen, M Nagasaka, SHI Ou… - JTO Clinical and …, 2023 - Elsevier
Introduction Oral administration of ritonavir-boosted nirmatrelvir (Paxlovid) was found to be
promising in the treatment of coronavirus disease 2019. The active antiviral component …

[PDF][PDF] Lipid-based nanoformulations for TKIs delivery in cancer therapy

ZA Radmoghaddam, S Honarmand… - NanoScience …, 2022 - jnanoscitec.com
Cancer therapy faces many challenges, such as inadequate drug loading, low solubility,
leakage before reaching the target cells and killing healthy cells. Furthermore, severe side …

[HTML][HTML] Ferroptosis: Frenemy of Radiotherapy

L Kerkhove, F Geirnaert, I Dufait… - International Journal of …, 2024 - mdpi.com
Recently, it was established that ferroptosis, a type of iron-dependent regulated cell death,
plays a prominent role in radiotherapy-triggered cell death. Accordingly, ferroptosis inducers …

[HTML][HTML] Lost in translation: Revisiting the use of tyrosine kinase inhibitors in colorectal cancer

KK Iyer, NP van Erp, DVF Tauriello… - Cancer Treatment …, 2022 - Elsevier
Patients with advanced or metastatic colorectal cancer ((m) CRC) have limited effective
treatment options resulting in high mortality rates. A better understanding of the molecular …

[HTML][HTML] Exploring the impact of novel anti-cancer therapies on jaw osteonecrosis and other bones: A comprehensive review

W Konarski, T Poboży, K Konarska… - Journal of Clinical …, 2024 - mdpi.com
Osteonecrosis is a debilitating condition characterized by the loss of blood supply to the
bones, leading to bone death. This condition can impact various bones, including the jaw …